Lazard Capital Upgrades Progenics Pharmaceuticals (PGNX) to Buy
PGNX Hot Sheet
Rating Summary:2 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Lazard Capital upgrades Progenics Pharmaceuticals (Nasdaq: PGNX) from Hold to Buy.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- UPDATE: Nomura Securities Upgrades Central European Distribution (CEDC) to Neutral; Strategic Alliance with Russian Standard
- KBW Upgraded Commerce Bancshares (CBSH) to Market Perform
Create E-mail Alert Related Categories
UpgradesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
